Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVITROL Safety in Health Care Professionals
NCT00834080Phase 3Completed
- Sponsor
- Alkermes
- Start
- Mar 2009
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of naltrexone in opioid use disorder (OUD), sponsored by Alkermes. Primary endpoint: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event at 2 years. Started Mar 2009; status: completed.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00834080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00834080.